SAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in ...
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were presented, comparing tirzepatide to semaglutide for their impact ...
Autonomix (AMIX) Medical announced new longer-term post hoc data from its initial trial phase of its first-in-human study proof-of-concept evaluating the safety and effectiveness of delivering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback